The ARRIVE Guidelines Checklist * Animal Research: Reporting In Vivo Experiments

Provide an accurate summary of the background, research objectives, including details of the species or strain of animal used, key methods, principal findings and conclusion of the study.

[1]  Merlin C. Thomas,et al.  Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice , 2012, Diabetes.

[2]  S. Parasuraman,et al.  Measurement of invasive blood pressure in rats , 2012, Journal of pharmacology & pharmacotherapeutics.

[3]  I. Cuthill,et al.  Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research † , 2012, Osteoarthritis and cartilage.

[4]  J. Annereau,et al.  Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. , 2011, Biochemical pharmacology.

[5]  王林,et al.  CONSORT , 2011 .

[6]  N. Osheroff,et al.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. , 2011, Biochemistry.

[7]  C. Bailly,et al.  Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system , 2011, Investigational New Drugs.

[8]  F. J. López Hernández,et al.  Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications , 2011, Journal of Translational Medicine.

[9]  M. Miller,et al.  Classification of Canine Malignant Lymphomas According to the World Health Organization Criteria , 2011, Veterinary pathology.

[10]  J. Annereau,et al.  A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. , 2010, Leukemia research.

[11]  Feng-ying Lei,et al.  Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril. , 2010, Experimental and molecular pathology.

[12]  C. Bonnefont,et al.  A Morphological Study of 608 Cases of Canine Malignant Lymphoma in France With a Focus on Comparative Similarities Between Canine and Human Lymphoma Morphology , 2010, Veterinary pathology.

[13]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Trials.

[14]  C. Khanna,et al.  Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.

[15]  P. Valent,et al.  Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature. , 2009, In vivo.

[16]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[17]  J. Annereau,et al.  F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. , 2008, Cancer research.

[18]  L. Lewis,et al.  Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. , 2008, American journal of veterinary research.

[19]  M. Seckl,et al.  Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity , 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[20]  P. Xie,et al.  Diabetic Nephropathy: Mechanisms of Renal Disease Progression , 2008, Experimental biology and medicine.

[21]  Alessandra Montecucco,et al.  Cellular response to etoposide treatment. , 2007, Cancer letters.

[22]  S. Dow,et al.  Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. , 2007, Journal of veterinary internal medicine.

[23]  Ban Liu,et al.  [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[24]  D. Booth.  Online submission , 2006, Quaternary Research.

[25]  M. Kretzler,et al.  Integrin-linked kinase in renal disease: connecting cell–matrix interaction to the cytoskeleton , 2005, Current opinion in nephrology and hypertension.

[26]  N. Komai,et al.  NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. , 2005, American journal of physiology. Renal physiology.

[27]  D. Casarini,et al.  High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. , 2004, American journal of physiology. Renal physiology.

[28]  H. Parving,et al.  Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy , 2004, Current opinion in nephrology and hypertension.

[29]  M. Mcentee,et al.  Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. , 2003, Veterinary and comparative oncology.

[30]  G. King,et al.  Molecular understanding of hyperglycemia's adverse effects for diabetic complications. , 2002, JAMA.

[31]  J. Siderov,et al.  Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide , 2002, British Journal of Cancer.

[32]  A. Woods,et al.  The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. , 2001, The American journal of pathology.

[33]  H. Parving.  Diabetic nephropathy: prevention and treatment. , 2001, Kidney international.

[34]  Ashutosh Kumar Singh,et al.  Role of angiotensin II in diabetic nephropathy. , 2000, Kidney international. Supplement.

[35]  S. Zeuzem,et al.  Involvement of the platelet‐derived growth factor receptor in angiotensin II‐induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells , 2000, FEBS letters.

[36]  V. Chábová.  [Pathophysiology of diabetic nephropathy]. , 1999, Casopis lekaru ceskych.

[37]  K. Hande,et al.  Etoposide: four decades of development of a topoisomerase II inhibitor. , 1998, European journal of cancer.

[38]  U. Sauer,et al.  High glucose-induced TGF-beta 1 regulates mesangial production of heparan sulfate proteoglycan. , 1996, The American journal of physiology.

[39]  S. Joel,et al.  The clinical pharmacology of etoposide: an update. , 1996, Cancer treatment reviews.

[40]  E. Ruoslahti,et al.  Transforming growth factor-beta in disease: the dark side of tissue repair. , 1992, The Journal of clinical investigation.

[41]  R. Carey,et al.  Expression of alpha-smooth muscle actin in the developing kidney vasculature. , 1992, Hypertension.

[42]  Harry E. Jacobson.  Chronic renal failure: pathophysiology , 1991, The Lancet.

[43]  R. Matus,et al.  Etoposide (VP-16). Retrospective analysis of treatment in 13 dogs with lymphoma. , 1990, Journal of veterinary internal medicine.

[44]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[45]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Gregory K. Ogilvie,et al.  Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog. , 1988, American journal of veterinary research.

[47]  E. Masini,et al.  Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog , 1985, Agents and Actions.

[48]  N. El-Sherif,et al.  Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs , 1982, Journal of cardiovascular pharmacology.

[49]  G. Giovannoni,et al.  Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. , 2012, Multiple sclerosis and related disorders.

[50]  K. Jung,et al.  TGF-beta1-induced PINCH-1-ILK-alpha-parvin complex formation regulates mesangial cell proliferation and hypertrophy. , 2007, Experimental & molecular medicine.

[51]  S. Kaul,et al.  Assessment of Toxicokinetics and Toxicodynamics Following Intravenous Administration of Etoposide Phosphate in Beagle Dogs , 2004, Pharmaceutical Research.

[52]  P. Trail,et al.  Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30 , 2004, Investigational New Drugs.

[53]  Giuseppe Remuzzi,et al.  Clinical practice. Nephropathy in patients with type 2 diabetes. , 2002, The New England journal of medicine.

[54]  P. Sonneveld,et al.  Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. , 2000, Haematologica.

[55]  J. H. Oh,et al.  Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. , 1998, Kidney international.

[56]  W. Border,et al.  Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. , 1998, Kidney international.

[57]  F. Locatelli,et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.